Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study
David Gordon,1 Edward T Hellriegel,1 Heidi Rath Hope,2 David Burt,1 Joseph B Monahan2 1Research and Development, Aclaris Therapeutics, Inc., Wayne, PA, USA; 2Research and Development, Aclaris Therapeutics, Inc., and Confluence Discovery Technologies, Inc., St. Louis, MO, USACorrespondence: David Gor...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-06-01
|
| Series: | Clinical Pharmacology : Advances and Applications |
| Subjects: | |
| Online Access: | https://www.dovepress.com/safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-the-mk2-i-peer-reviewed-fulltext-article-CPAA |